Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980
| Autor: | Hailing Guo, Diego Bellido, Vanita R. Aroda, Elisabeth Niemoeller, Elisabeth Souhami, Jeffrey Unger, Akane Takami, Richard M. Bergenstal, Carol Wysham, Julio Rosenstock, Guillermo González-Gálvez |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endpoint Determination Endocrinology Diabetes and Metabolism Drug Evaluation Preclinical Insulin Glargine Titratable acid Type 2 diabetes Body Mass Index law.invention Lixisenatide chemistry.chemical_compound Randomized controlled trial law Internal medicine Diabetes mellitus Internal Medicine Humans Hypoglycemic Agents Insulin Medicine Aged Glycated Hemoglobin Advanced and Specialized Nursing Errata Dose-Response Relationship Drug business.industry Insulin glargine Basal insulin Body Weight Middle Aged medicine.disease Metformin Drug Combinations Treatment Outcome Diabetes Mellitus Type 2 chemistry Female Peptides business medicine.drug |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 |
| Popis: | This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents.After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/mHbACompared with iGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|